NCT06678659View on ClinicalTrials.gov

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

October 30, 2028

Study Completion Date

October 30, 2028

Conditions
UnresectableLocally AdvancedMetastatic CancersRelapsed/Refractory Lymphomas
Interventions
DRUG

REC-1245

Oral

Trial Locations (6)

37203

RECRUITING

SCRI Oncology Partners - PPDS, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

84119

RECRUITING

START Mountain Region, West Valley City

91010

RECRUITING

City of Hope, Duarte

M5G 1X6

RECRUITING

Princess Margaret Cancer Centre, Toronto

H4A3J1

RECRUITING

McGill University Health Centre (MUHC) - The Montreal, Québec

All Listed Sponsors
lead

Recursion Pharmaceuticals Inc.

INDUSTRY